

## INDEX

Contents	Page No.
<b>List of Figures</b>	xii
<b>List of Tables</b>	xix
<b>Abbreviations and Symbols</b>	xxi
<b>Preface</b>	xxv
<b>CHAPTER 1. INTRODUCTION</b>	1
1.1 Alzheimer's disease	1
1.2 AD-molecular mechanisms and major targets involved	2
1.2.1 Cholinergic hypothesis	3
1.2.2 Amyloid beta (A $\beta$ ) hypothesis	5
1.2.3 Tau hypothesis	6
1.2.4 Oxidative stress hypothesis	8
1.2.5 MAO inhibition	9
1.2.6 NMDA receptor inhibition	9
1.2.7 HDAC inhibition	10
1.2.8 Cyclase inhibition	11
1.2.9 Exopeptidase inhibition	11
1.2.10 Lipid dyshomeostasis in AD	12
1.2.11 Pathogenic involvement of Porphyromonas gingivalis in AD	13
1.2.12 Neurovascular dysfunction in AD	13
1.3 Modern strategies to develop novel compounds for AD treatment	14
1.3.1 Multi-targeting ligand treatment strategy	14
1.3.2 Computer-aided drug design approach	15
1.3.3 Molecular hybridization	16
1.4 Design hypothesis in the present study	17
<b>CHAPTER 2. REVIEW OF LITERATURE</b>	19
2.1 Benzylpiperidine and benzylpiperazine derivatives as MTDL for AD	19
2.2 Quinazoline derivatives	26
2.3 Drugs under clinical investigations for AD	38
2.3.1 Phase I	39
2.3.2 Phase II	39
2.3.3 Phase III	42
2.4 Available neuro-therapeutics for AD treatment	45
<b>CHAPTER 3. RATIONALE, OBJECTIVES AND PLAN OF WORK</b>	48
3.1. Rationale and objectives	48
3.1.1 Designing of Part-I MTDLs	50

Contents	Page No.
3.1.2 Designing of Part-II MTDLs	53
3.2. Plan of work	55
3.3 Significance of the study	58
<b>CHAPTER 4. EXPERIMENTAL</b>	<b>59</b>
4.1 Computational studies	59
4.1.1 Pharmacophore modelling and Phase Screening	59
4.1.2 Virtual Screening and Docking post processing	60
4.1.3 Mechanics-Generalized Born Surface Area (MM-GBSA)	60
4.1.4 Molecular docking studies	61
4.1.5 Molecular Dynamics and Simulation studies	61
4.1.6 ADME drug-likeness analysis	62
4.1.7 DFT-based computational studies	62
4.2 Synthesis	63
4.2.1 Chemicals and reagents	63
4.2.2 Synthesis of Series I ( <b>AV-1 to AV-21</b> )	63
4.2.2.1 General procedure for the synthesis of intermediate <b>9c-15c</b>	64
4.2.2.2 General procedure for the synthesis of <b>16d-22d</b>	65
4.2.2.3 General procedure for the synthesis of <b>AV-1 to AV-21</b>	65
4.2.3 Synthesis of Series II ( <b>AK-1 to AK-14</b> )	66
4.2.3.1 General procedure for the synthesis of <b>2b</b>	66
4.2.3.2 General procedure for the synthesis of <b>3b</b>	67
4.2.3.3 General procedure for the synthesis of <b>AK-1 to AK-14</b>	67
4.3 Characterization of the synthesized compounds	67
4.3.1 Melting point	67
4.3.2 TLC ( $R_f$ value)	68
4.3.3 HPLC percentage purity determination	68
4.3.4 FT-IR	68
4.3.5 $^1\text{H}$ NMR and $^{13}\text{C}$ NMR	68
4.3.6 Mass spectra	69
4.3.7 Single crystal X-Ray Crystallography	69
4.4 Pharmacology	69
4.4.1 <i>In-vitro</i> studies	69
4.4.1.1 Cholinesterase inhibition assay (hAChE and hBChE)	69
4.4.1.2 Enzyme kinetics study	70

Contents	Page No.
4.4.1.3 Enzyme reversibility study	71
4.4.1.4 BACE-1 inhibition assay	71
4.4.1.5 PAMPA-BBB assay	72
4.4.1.6 Propidium iodide displacement assay	73
4.4.1.7 A $\beta$ inhibition-thioflavin T assay	73
4.4.1.8 Microscopic (AFM and confocal) studies	74
4.4.1.9 Neurotoxicity estimation on differentiated SH-SY5Y cell lines	75
4.4.1.10 H <sub>2</sub> O <sub>2</sub> induced Neuroprotective estimation on differentiated SH-SY5Y cell lines	76
4.4.1.11 A $\beta$ <sub>1-42</sub> induced Neuroprotective estimation differentiated SH-SY5Y cell lines	76
4.4.2 <i>In vivo and ex-vivo studies</i>	77
4.4.2.1 Animals	77
4.4.2.2 Acute toxicity studies	77
4.4.2.3 Scopolamine-induced amnesia model for testing cognition enhancement in rats	77
4.4.2.4 <i>Y-maze test</i>	78
4.4.2.5 <i>Ex-vivo</i> and biochemical analysis	78
4.4.2.6 A $\beta$ <sub>1-42</sub> induced ICV rat model: Morris water maze test	80
4.4.2.7 Western blot studies	81
4.4.2.8 Immunohistochemistry analysis	82
4.4.2.9 Brain histopathology	83
4.4.2.10 <i>In-vivo</i> blood-brain permeability	83
4.4.2.11 <i>Drosophila</i> phenotypic model	84
4.4.2.11.1 Compound <b>AK-2</b> toxicity analysis	84
4.4.2.11.2 Cell Viability in <b>AK-2</b> in AD flies	84
4.4.2.11.3 <i>Drosophila</i> eye phenotype	85
4.4.2.12 Pharmacokinetic studies	85
<b>CHAPTER 5. RESULTS AND DISCUSSION</b>	86
5.1 PART-I: SERIES I	86
5.1.1 Computational studies	86
5.1.1.1 Pharmacophore modelling	86
5.1.1.2 Virtual screening	90
5.1.1.3 MM-GBSA	92
5.1.1.4 Molecular Docking	92
5.1.1.5 Molecular Dynamics Simulation	95

Contents	Page No.
5.1.1.6 Density Functional Theory (DFT) studies	100
5.1.1.7 QikProp analysis	102
5.1.2 Chemistry	103
5.1.2.1 Synthesis of Series I ( <b>AV-1</b> to <b>AV-21</b> )	103
5.1.2.2 Characterization of the intermediates ( <b>9c</b> to <b>15c</b> )	104
5.1.2.3 Characterization of the intermediates ( <b>16d</b> to <b>22d</b> )	106
5.1.2.4 Characterization of the targeted compounds ( <b>AV-1</b> to <b>AV-21</b> )	108
5.1.2.5 Single crystal X-ray crystallography	117
5.1.3 Pharmacology	118
5.1.3.1 <i>In-vitro</i> studies	118
5.1.3.2 <i>In-vivo</i> and <i>ex-vivo</i> studies	130
5.2 PART-II: SERIES II–III	142
5.2.1 Chemistry	142
5.2.1.1 Synthesis of Series II ( <b>AK-1</b> to <b>AK-14</b> )	142
5.2.1.2 Characterization of the intermediate <b>2b</b>	143
5.2.1.3 Characterization of the intermediate <b>3b</b>	144
5.2.1.4 Characterization of the targeted compounds ( <b>AK-1</b> to <b>AK-14</b> )	144
5.2.1.5 Single crystal X-ray crystallography	149
5.2.2 <i>In-vitro</i> biological evaluations	151
5.2.2.1 <i>In-vitro</i> studies	164
5.2.2.2 <i>In-vivo</i> and <i>ex-vivo</i> studies	157
5.2.3 Computational studies	174
5.2.3.1 Molecular docking studies	174
5.2.3.2 MD simulation studies	180
5.2.3.3 MM-GBSA analysis	183
5.2.3.4 ADME drug-likeness analysis	184
5.2.3.5 DFT-based computational studies	185
<b>CHAPTER 6. SUMMARY AND CONCLUSION</b>	191
6.1 Conclusion	191
6.2 Scope and future directions	193
<b>CHAPTER 7. REFERENCES</b>	195
<b>CHAPTER 8. APPENDIX</b>	229
8.1. <sup>1</sup> H and <sup>13</sup> C spectra of representative synthesized compounds	229
8.2. Mass spectrum of the representative compounds	274
8.3 HPLC chromatogram of the representative compounds	284

---

<b>Contents</b>	<b>Page No.</b>
8.4 Alpha-ATR spectra of the representative compounds	292
<b>LIST OF PUBLICATIONS</b>	299

---